title: Clinical outcome following the use of inadequate solutions for continuous veno-venous hemodiofiltration.
abstract: BACKGROUND
  A short time ago, commercially available diafiltration and replacement fluids could be found o n the hospital in Turkey. Instead, peritoneal dialysis solution (PDS) for continue veno-venous hemodiafiltration (CVVHDF) therapy and normal saline as replacement fluid are used. In this retrospective study, we investigated the effects of PDS and bicarbonate-buffered hemofiltration solution (Bic-HFS).
  
  
  METHODS
  We did a retrospective chart review of 24 patients treated with continue renal replacement therapy (CRRT) between January 2004 and February 2008. Peritoneal dialysis solution (PDS) was used in 14 patients, and bicarbonate-buffered hemodialysis solution (bic-HFS) was used in 10 patients.
  
  
  RESULTS
  Demographic data, laboratory findings, and mortality rate were similar both groups. Blood glucose and lactate levels were higher in the PD group than the bic-HFS group (p < 0.05). Hyperglycemia occurred more frequent in the PDS group than in the bic-HFS group (64% versus 30%, respectively; p < 0.05). Metabolic acidosis occurred in eight patients (57%) in the PDS group and three patients (30%) in the bic-HFS group (p < 0.05). Hypotension was higher in the PDS group (10, 71%) than in the bic-HFS group (3, 30%; p < 0.05).
  
  
  CONCLUSIONS
  Using PDS fluid as dialysate for CVVHDF therapy is not a preferable solution because of the metabolic disturbances that it can cause.
authors.affiliation: Meram Medicine Faculty, Department of Anaesthesiology, Selcuk University, Konya, Turkey. jalecelik@hotmail.com
authors.forename: Jale Bengi
authors.initials: JB
authors.lastname: Celik
authors.forename: Ahmet
authors.initials: A
authors.lastname: Topal
authors.forename: Elmas
authors.initials: E
authors.lastname: Kartal
authors.forename: Alper
authors.initials: A
authors.lastname: Yosunkaya
mesh_terms: D000138:Acidosis / Q000209:etiology*; D058186:Acute Kidney Injury / Q000150:complications / Q000628:therapy*; D000368:Aged; D015314:Dialysis Solutions / Q000009:adverse effects* / Q000592:standards; D005260:Female; D017583:Hemodiafiltration; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015314:Dialysis Solutions